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Objective: Assessment of walking distance by treadmill testing is the most commonly used method to evaluate the effect
of treatment in patients with peripheral arterial disease. However, treadmill testing is time consuming, relatively
expensive, and does not adequately reflect real life functional ability. We hypothesized that the Walking Impairment
Questionnaire (WIQ) could be an alternative tool to assess objective improvement in functional walking ability of
patients with intermittent claudication.
Methods: This was a validation study. It was conducted through the outpatient clinic for vascular surgery. Patients with
intermittent claudication were referred for supervised exercise therapy. Treadmill testing (absolute claudication distance
[ACD]), WIQ, and quality of life questionnaires (RAND-36 and EuroQol) were administered at study onset and after 3
months of supervised exercise therapy. Responsiveness was determined by mean changes in and correlation coefficients of
WIQ, ACD, and quality of life questionnaires. Patients were categorized into quartiles based on the increase in ACD,
which were subsequently related to change in WIQ and quality of life.
Results:The mean pre- and post-treatment total WIQ scores of 91 patients were 0.45 (0.22) and 0.58 (0.22), respectively.
The correlation coefficient between the change in total WIQ score and ACD was 0.331 (P .004). A 0.1 change in total
WIQ score corresponded to a change of 345 meters in ACD. Analysis of the four quartiles compared to an increase in
ACD showed that a greater increase in ACD corresponded with a greater increase in WIQ score, from 0.06 to 0.25 (P 
.011).
Conclusion: These data indicate that the WIQ is a valid tool to detect improvement or deterioration in the daily
walking ability of patients with intermittent claudication. Hence, the WIQ can be used as an alternative to treadmill
testing for objective assessment of functional walking ability, both in daily practice and in clinical trials. ( J Vasc
Surg 2009;50:89-94.)Intermittent claudication decreases functional capacity,
walking ability1 and quality of life.2 It is increasingly recog-
nized that assessment of functional capacity and walking
ability are important in determining disease severity and
evaluating treatment in patients with intermittent claudica-
tion. Treadmill testing is currently the most commonly
used measure to assess walking ability as expressed in
meters. However, a large discrepancy often exists among
subjectively experienced daily walking ability,3,4 objective
severity of the disease,5 and walking ability as measured on
a treadmill6 in a vascular laboratory. Furthermore, treadmill
testing requires adequate equipment and personnel, is time
consuming, and is relatively expensive. A qualitative ap-
proach to document daily walking ability is the Walking
Impairment Questionnaire (WIQ),7 a validated question-
naire which is short, easy to complete, and inexpensive. The
questionnaire evaluates walking ability with a focus on
walking distance, walking speed, and the ability to climb
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doi:10.1016/j.jvs.2008.12.073stairs.8,9 The WIQ has been used in studies to evaluate the
effect of treatment in patients with peripheral arterial dis-
ease.10-12 Furthermore, one study showed that the WIQ is
also capable of gauging cardiovascular risk status in patients
with peripheral arterial disease.13 A recent study suggests
that the WIQ is the most specific questionnaire to evaluate
walking ability in patients with peripheral arterial disease,
and that the WIQ correlates best with the ambulatory
limitations as measured on a treadmill.14 However, more
important is the association between a change inWIQ score
and a clinical improvement or deterioration in walking
ability in assessing the effect of treatment. In this study, we
hypothesized that the WIQ, which can be administered
within 5 minutes and inexpensively, can be used as an
alternative tool to detect objective improvement in func-
tional ability in response to supervised exercise therapy in
patients with intermittent claudication.
PATIENTS AND METHODS
Patients. Consecutive patients presenting at the out-
patient clinic for vascular surgery with intermittent claudi-
cation (Rutherford stage 1-3 or Fontaine stage II) were
included in the study. Diagnosis of intermittent claudica-
tion was confirmed with an ankle-brachial index (ABI)
measurement 0.9 at rest or decreasing 0.15 after exer-
cise.15 Inclusion criteria were the ability to walk on a
treadmill (3.2 km/hour) before treatment was initiated, as
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on a treadmill. An exclusion criterion was cessation of the
treadmill test due to factors other than intermittent claudi-
cation, eg, a cardiopulmonary or orthopedic disorder that
limited the walking distance. Informed consent was ob-
tained from all patients, and the study was approved by the
medical ethics committee of the Atrium Medical Centre
Parkstad.
Supervised exercise therapy. For symptomatic relief,
patients were treated with supervised exercise therapy.16,17
Exercise therapy is recommended as the primary mode of
treatment for patients with intermittent claudication,15 and
supervised exercise therapy has been shown to have an addi-
tional benefit over nonsupervised exercise therapy in improv-
ing walking distance.18 All patients were referred to a physio-
therapist participating in the Network for Exercise Therapy
Parkstad (NETP).16 The NETP provides community-
based supervised exercise therapy in private physiotherapy
practices equally distributed over the region, instead of a
department of physiotherapy and rehabilitation in a hospi-
tal or rehabilitation clinic. This approach has been demon-
strated to be as equally effective in providing symptomatic
improvement as a clinic-based approach,17,19 with the ad-
ditional advantage of close proximity to the patient’s home
address. Furthermore, all patients received a platelet inhib-
itor, cholesterol lowering medication, and smoking cessa-
tion and lifestyle advice by a trained nurse practitioner as
part of the standard treatment protocol.
WIQ. The WIQ, treadmill testing and administration
of quality of life questionnaires were administered at the
start of the study and after 3 months of supervised exercise
therapy. The WIQ is a short, easy to complete, disease-
specific questionnaire validated in patients with intermit-
tent claudication.7-9 We used the revised version of the
WIQ,9 that has recently been adapted and validated for the
European metric system and specifically the Dutch lan-
guage.20 The questionnaire was self-administered by the
patients, as validated by Coyne et al,9 and contains three
domains measuring three important factors of walking im-
pairment in patients with intermittent claudication: walk-
ing distance, walking speed, and the ability to climb stairs.
For each separate domain, a subscore of the Likert items
was calculated with a Likert scale. The total WIQ score was
defined as themean of the three subscores, and was recently
validated.20
Treadmill testing. To assess walking distance, all pa-
tients performed a standardized graded treadmill test with a
constant speed of 3.2 km/hour, starting at 0% incline and
increasing 2% every 2 minutes.21 For practical reasons,
during the follow-up measurements the inclination and
duration of the test were maximized to 10% and 30minutes
(1600 meters), respectively. Test variables during treadmill
testing were the absolute claudication distance (ACD),
defined as the distance that severe claudication pain forces
cessation of exercise, and the initial claudication distance
(ICD), which is the moment the patient prefers to stop due
to claudication pain.Quality of life questionnaires. Quality of life was
assessed with the RAND-36 and the European Quality of
life (EuroQol) instruments. The RAND-36 is a generic
quality of life instrument that provides an 8-scale profile of
functional health and well-being. It is an exact replica of the
Short Form 36 (SF-36), except for use of a different scoring
algorithm.22 The 8 domains of assessing quality of life are
physical functioning, social functioning, physical role im-
pairment, emotional role impairment, mental health, vital-
ity, pain, and general health experience.23 Scores range
between 0 and 100, with 0 expressing the worst health
status and 100 the best. We used the validated Dutch
RAND-36 for evaluation in this study.24 The EuroQol, a
two-part questionnaire, is designed to measure general
health25 and consists of an overall health classification index
containing five questions to evaluate physical functioning
(mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression). The EuroQol classifies patients into a
health state which is calculated with an algorithm ranging
from 0 to 1.26 Furthermore, health status was assessed by a
visual analogue scale (VAS), with 0 expressing the worst
health state and 100 the best.
Statistical analysis. Walking distances are presented
as median and interquartile-range (IQR) since they were
not normally distributed. The statistical significance of the
WIQ was analyzed with a paired t test, and walking dis-
tances were analyzed with a Wilcoxon Signed Ranks Test.
To evaluate the ability of the WIQ to detect objective
improvement, we calculated mean changes between base-
line and 3 months of supervised exercise therapy with
respect to the WIQ, walking distances (ICD and ACD),
and generic quality of life questionnaires. Correlations were
calculated with the Spearman correlation coefficients. Uni-
variate linear regression analysis was used to demonstrate
the dependency of the change in total WIQ score on the
change in ACD.
We next determined whether the change in WIQ at the
3-month follow-up was related to the change in walking
distance (ACD). Since it is inappropriate to use summary
statistics on percentage changes due to improper cancella-
tion of positive and negative changes,27 we used a linear
regression model to categorize the response to treatment.
To this end, the expected ACD at 3months for each patient
was calculated with univariate linear regression analysis,
with baseline ACD as the independent variable. For each
individual, the difference between expected and actually
measured ACD at 3 months was calculated. These calcu-
lated differences for the entire study population were di-
vided into quartiles and patients were correspondingly cat-
egorized into 4 responder groups. Changes in WIQ,
RAND-36, and EuroQol were related to the responder
groups. One-way ANOVA testing was performed to ana-
lyze the changes in WIQ, RAND-36, and EuroQol for the
four responder groups, ie, to determine whether improve-
ment in these scores correlated with improvement in walk-
ing distance. Statistical analyses were performed using SPSS
15.0 for Windows (Microsoft, Redmond, Wash), version
15.0 (SPSS Inc, Chicago, Ill).
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This study included 91 consecutive patients with a
mean age of 66.2 years. All patients were asked to fill out a
self-administered WIQ; the mean ABI was 0.72 at rest.
Baseline characteristics of the study population are pre-
sented in Table I.
WIQ and walking distances. The total WIQ score as
well as the score for each of the three WIQ subdomains
were significantly higher at 3 months after initiation
of supervised exercise therapy as compared with baseline
(Table II), indicating an improvement in functional walk-
ing ability as assessed by the questionnaire. The mean
change in total WIQ score was 0.14 (standard deviation
[SD] 0.19). Walking distances as assessed by treadmill
testing in the vascular laboratory also significantly im-
proved. After 3 months of supervised exercise therapy,
walking distance of 11 out of 91 patients was truncated by
the maximal duration of 30 minutes of the treadmill test
(1600meters). The ICD improved from 179 to 330meters
(median), while the ACD improved from 245 to 460
meters (median) (P  .001). The correlation between the
increase in WIQ and increase in ACD is presented in
the Fig. The Spearman correlation coefficient between the
change in total WIQ score and the change in ACD was
0.331 (P  .004). Furthermore, univariate linear regres-
sion analysis showed a dependency of the change in total
WIQ score on the change in ACD (P .001). A change of
0.1 in totalWIQ score corresponded to a change in ACDof
345 meters.
WIQ and quality of life. Results for the RAND-36
and EuroQol pre- and post-treatment are shown in Table
III. For each of the subdomains of the RAND-36 and the
EuroQol, a higher score indicates an improvement. The
largest effects of treatment were found for the subdomains
physical functioning and pain of the RAND-36, with mean
changes of 7.9 and 7.7, respectively, from pre-treatment to
post-treatment (Table III). The index score of the EuroQol
Table I. Baseline characteristics of the study population
Study population n  91
Age – mean (SD) 66.2 (9.6)
Men - % 61.5
BMI - mean (SD) 27.6 (4.7)
Resting ABI - mean (SD) 0.72 (0.17)
Smoking
Never - % 6.6
Stopped smoking - % 39.6
Current smoker - % 53.8
Hypertension - % 64.8
Hypercholesterolemia - % 66.7
Diabetes mellitus - % 26.4
Coronary heart disease - % 19.8
Stroke or TIA - % 16.5
COPD - % 31.9
SD, Standard deviation; BMI, body mass index; ABI, ankle brachial index;
TIA, transient ischemic attack; COPD, chronic obstructive pulmonary dis-
ease.increased from 0.64 to 0.70. No significant correlationbetween the change in subdomains of the RAND-36 or
EuroQol scores and the change in total WIQ score was
found.
Practical implications. Patients were divided into re-
sponder groups based on the difference between expected
and measured ACD post-treatment. In Table IV, quartiles
based on this difference were related to the change inWIQ.
In the first quartile, the response was 248 meters or less
than expected, in the second quartile the response ranged
between 248 and 108.5 meters less than expected, in the
third quartile the response was between 108.5 meters less
and 62 meters more than expected, and in the fourth
quartile the response was more than 62 meters than ex-
pected. Over these four quartiles, the total WIQ scores
significantly improved from 0.06 to 0.25 (P  .011). This
indicates that a qualitative improvement in walking ability
as assessed by the questionnaire shows good correspon-
dence with a quantitative improvement in walking distance
as assessed by treadmill testing. In line with this, the sub-
domain physical functioning of the RAND-36 showed a
(non-significant) increase from 2.8 to 13.0 (P  .118).
DISCUSSION
The aim of the study was to determine whether the
Walking Impairment Questionnaire can be used as an alter-
native tool to treadmill testing in assessing improvement in
functional ability in patients with intermittent claudication
treated with supervised exercise therapy. The findings in
the present study show that the WIQ is a reliable instru-
ment and alternative to treadmill testing in determining the
effect of treatment in patients with intermittent claudica-
tion.
Our data demonstrate that patients with intermittent
claudication treated with supervised exercise therapy for 3
months show a gradual increase in their WIQ score; fur-
thermore, the higher theWIQ score the better the patient’s
functional walking ability. We correlated the WIQ score
with the absolute claudication distance to demonstrate that
an increase in WIQ corresponds to an increase in walking
distance in meters as assessed by the gold standard treadmill
test. The correlation coefficient of 0.331 may appear to be
modest; however, similar studies comparing objective and
subjective instruments to assess the effect of an interven-
tion do not closely correlate.11,28 The three statistical
methods, including Spearman correlation, linear regres-
sion analysis, and responder group analysis, support a
similar conclusion, showing that a qualitative improve-
ment in walking ability as assessed by the questionnaire
corresponds with a quantitative improvement in walking
distance as assessed by treadmill testing. Even more impor-
tant than the correlation coefficient, responder group anal-
ysis showed the ability of the WIQ to detect an effect of
treatment. The findings in the present study, therefore,
justify the use of the total WIQ score as an alternative to
treadmill testing as a primary outcome measurement to
assess the efficacy of supervised exercise therapy in patients
with intermittent claudication. In line with this, the WIQ is
also expected to be a useful tool for assessment of the
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(eg, percutaneous vascular interventions or vascular sur-
gery).
In trials, the success of therapies and comparison
among treatments has traditionally been determined by
treadmill testing or measurement of ABI. Do we then need
an alternative instrument to assess efficacy of treatment?
Although treadmill testing has been the gold standard for
measuring walking distance in meters,29 this method has
several important limitations. Treadmill testing has face
validity for functional walking distance; however, a large
variation has been reported regarding daily walking ability
and claudication walking distances as measured on a tread-
mill,3,4 resulting in an unrealistic representation of daily life
walking ability. Furthermore, treadmill testing is time con-
suming, relatively expensive, requires adequate equipment
and personnel, and is not directly available for all physi-
cians. Another disadvantage of treadmill testing is that the
measured walking distance is dependent on applied tread-
Table II. WIQ and walking distances at baseline and after
Pre-treatment
Mean (SD)
WIQ
Distance 0.38 (0.26)
Speed 0.41 (0.22)
Stair climbing 0.55 (0.32)
Total score 0.45 (0.22)
Median (IQR) M
Walking distances
ICD 179 (120 to 260) 33
ACD 245 (168 to 380) 46
SD, Standard deviation;WIQ,Walking Impairment Questionnaire; ICD, ini
range.
*Paired t test.
**Wilcoxon Signed Ranks Test.
Fig. Change in Walking Impairment Questionnaire (WIQ) com-
pared to the change in absolute claudication distance 3 months
after treatment of intermittent claudication.mill protocols, which are not uniform and therefore ham-per its use in the comparison of the effects of treatments, eg,
in clinical trials. Other methods to evaluate walking dis-
tances without the use of a treadmill include the 6-minute
walking test,30-32 a shuttle walking test,31,33 a PADHOC
device,34 or the use of a global positioning system (GPS)
device.12 A recent study indicated that performance on
corridor-based functional measures (eg, a 6-minute walk-
ing test) is more closely linked to physical activity during
daily life than treadmill walking performance.32 Second,
with regard to the effectiveness of the ABI to determine the
effect of treatment in patients with intermittent claudica-
tion, studies have shown that a significant improvement in
walking ability is not necessarily associated with an increase
in ABI after supervised exercise therapy.35
To overcome the aforementioned limitations, theWIQ
was developed. The WIQ is designed as a disease-specific
questionnaire that assesses walking ability in patients with
peripheral arterial disease. Use of the WIQ in evaluation
and assessment has several benefits. First, the WIQ is short,
easy to complete, and inexpensive. The original version of
the WIQ was an interviewer-administered questionnaire8
and, for practical reasons, it has been modified to a vali-
dated self-administered or telephone-administered ques-
tionnaire.9 Second, the WIQ assesses functional walking
ability, including walking distance, walking speed, and the
ability to climb stairs. These items more realistically reflect
a patient’s daily life walking capacity than treadmill testing.
The improvement in functional walking ability after 3
months of supervised exercise therapy was not reflected by
an improvement in quality of life, as assessed by two generic
quality of life questionnaires. Although the RAND-36 and
EuroQol are the most widely used, generic quality of life
questionnaires, disease-specific questionnaires, such as the
CLAUS and VascuQol, may be more appropriate to deter-
mine the responsiveness to treatment in patients with pe-
ripheral arterial disease.36,37 Therefore, the use of the WIQ
for quality of life assessment will be the subject of future
onths of supervised exercise therapy
treatment
P value
Change
an (SD) Mean (SD)
5 (0.29) .001* 0.18 (0.28)
2 (0.22) .001* 0.11 (0.20)
8 (0.29) .001* 0.14 (0.29)
8 (0.22) .001* 0.14 (0.19)
n (IQR) Median (IQR)
23 to 480) .001** 135 (40 to 290)
08 to 593) .001** 200 (60 to 340)
udication distance;ACD, absolute claudication distance; IQR, interquartile3 m
Post-
Me
0.5
0.5
0.6
0.5
edia
0 (2
0 (3
tial clastudies.
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In conclusion, our findings demonstrate that the total
WIQ score can be used as an alternative to treadmill testing
for objective assessment of functional walking ability in
patients with intermittent claudication, both in daily prac-
Table III. Effect of treatment on quality of life
Pre-treatment
Mean (SD)
RAND-36
Functional status
Physical functioning 53.9 (17.4)
Social functioning 79.3 (21.6)
Role impairment (physical) 50.3 (38.7)
Role impairment (emotional) 81.7 (34.5)
Well-being
Mental health 76.8 (17.4)
Vitality 62.7 (19.5)
Pain 53.7 (18.7)
General evaluation
General health experience 53.3 (13.4)
Health
Change in health 38.2 (19.1)
EuroQol
Index score 0.64 (0.22)
VAS overall health 64.5 (20.5)
SD, Standard deviation; EuroQol, European Quality of Life; VAS, visual ana
*Wilcoxon Signed Ranks Test.
Table IV. Relation between qualitative improvement in w
improvement in walking distance as assessed by treadmill t
Quartile 1 Quart
Response 248
meters or less
than expected
Response be
to 108.5 m
than ex
WIQ
Distance 0.12 (0.27) 0.11 (
Speed 0.04 (0.20) 0.08 (
Stair climbing 0.04 (0.27) 0.10 (
Total score 0.06 (0.17) 0.10 (
RAND-36
Functional status
Physical functioning 2.8 (17.1) 7.4 (
Social functioning 1.1 (24.4) 3.1 (
Role impairment (physical) 18.2 (45.1) 1.3 (
Role impairment (emotional) 9.1 (40.1) 3.3 (
Well-being
Mental health 3.2 (19.6) 0.8 (
Vitality 11.1 (19.9) 6.3 (
Pain 0.4 (22.0) 4.6 (
General evaluation
General health experience 5.7 (16.1) 2.4 (
Health
Change in health 3.4 (25.9) 26.3 (
EuroQol
Index score 0.06 (0.18) 0.14 (
VAS overall health 3.2 (23.9) 9.3 (
WIQ, Walking Impairment Questionnaire; EuroQol, European Quality of L
Values are presented as mean change with standard deviations.
*One way ANOVA analysis.tice and in clinical trials.AUTHOR CONTRIBUTIONS
Conception and design: SN, LK, MP, JT
Analysis and interpretation: SN, ER, MP
Data collection: SN, ER, KG
Writing the article: SN, LK
Post-treatment
P value*
Change
Mean (SD) Mean (SD)
60.9 (19.0) .001 7.9 (17.2)
81.9 (21.4) .117 3.1 (21.5)
48.6 (38.0) .630 1.5 (40.0)
86.4 (30.2) .283 4.2 (36.4)
76.6 (19.2) .840 0.1 (14.7)
61.7 (19.9) .940 0.5 (20.9)
61.4 (21.3) .004 7.7 (23.1)
52.6 (13.5) .846 0.2 (14.7)
50.3 (24.3) .001 11.8 (28.2)
0.70 (0.18) .015 0.06 (0.24)
64.6 (17.3) .793 0.8 (20.9)
scale.
g ability as assessed by questionnaires and quantitative
g
Quartile 3 Quartile 4
P
value*
248
less
Response between 108.5 less
and 62 meters more than
expected
Response 62 meters
or more than
expected
0.18 (0.33) 0.30 (0.24) .113
0.13 (0.22) 0.23 (0.17) .016
0.20 (0.38) 0.22 (0.27) .152
0.18 (0.25) 0.25 (0.18) .011
13.5 (15.5) 13.0 (16.3) .118
4.2 (22.5) 3.6 (19.4) .971
13.2 (38.5) 3.6 (34.7) .075
11.7 (37.9) 6.3 (30.9) .354
5.2 (13.2) 0.8 (11.1) .324
4.0 (23.9) 2.4 (15.6) .028
13.9 (21.0) 6.8 (23.3) .197
7.4 (12.9) 2.5 (14.1) .014
21.3 (26.0) 13.6 (21.4) .001
0.10 (0.21) 0.00 (0.25) .022
1.4 (27.5) 1.0 (14.5) .326loguealkin
estin
ile 2
tween
eters
pected
0.25)
0.19)
0.20)
0.14)
16.1)
20.2)
34.8)
28.4)
13.7)
21.3)
20.2)
9.8)
26.3)
0.22)
16.6)
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